Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Volitionrx (VNRX) Accumulated Expenses (2019 - 2025)

Historic Accumulated Expenses for Volitionrx (VNRX) over the last 7 years, with Q3 2025 value amounting to $4.6 million.

  • Volitionrx's Accumulated Expenses rose 3174.9% to $4.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.6 million, marking a year-over-year increase of 3174.9%. This contributed to the annual value of $3.5 million for FY2024, which is 1150.13% down from last year.
  • Volitionrx's Accumulated Expenses amounted to $4.6 million in Q3 2025, which was up 3174.9% from $4.4 million recorded in Q2 2025.
  • Volitionrx's Accumulated Expenses' 5-year high stood at $4.6 million during Q3 2025, with a 5-year trough of $2.7 million in Q1 2023.
  • Its 5-year average for Accumulated Expenses is $3.5 million, with a median of $3.4 million in 2023.
  • As far as peak fluctuations go, Volitionrx's Accumulated Expenses tumbled by 2497.72% in 2022, and later skyrocketed by 3678.35% in 2023.
  • Quarter analysis of 5 years shows Volitionrx's Accumulated Expenses stood at $3.8 million in 2021, then dropped by 24.98% to $2.9 million in 2022, then soared by 36.78% to $3.9 million in 2023, then fell by 11.5% to $3.5 million in 2024, then soared by 31.87% to $4.6 million in 2025.
  • Its last three reported values are $4.6 million in Q3 2025, $4.4 million for Q2 2025, and $3.7 million during Q1 2025.